Radiomics markers that can predict the efficacy of first-line EGFR-TKI therapy are now more needed; we also have found two CT features for progression risk stratification to first-line EGFR-TKI remedy in advanced lung adenocarcinoma. This evidence concerns the gene EGFR and lung adenocarcinoma.